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Background: Induced pluripotent stem cells (iPSCs) derived from patients with neurodegenerative disease
generally lack neuropathological confirmation, the gold standard for disease classification and grading of severity.
The use of tissue with a definitive neuropathological diagnosis would be an ideal source for iPSCs. The challenge to
this approach is that the majority of biobanked brain tissue was not meant for growing live cells, and thus was not
frozen in the presence of cryoprotectants such as DMSO.
Results: We report the generation of iPSCs from frozen non-cryoprotected dural tissue stored at −80°C for up to
11 years. This autopsy cohort included subjects with Alzheimer’s disease and four other neurodegenerative diseases.
Conclusions: Disease-specific iPSCs can be generated from readily available, archival biobanked tissue. This allows
for rapid expansion of generating iPSCs with confirmed pathology as well as allowing access to rare patient variants
that have been banked.Background
Human iPSC-derived neural cells are attractive models
for Alzheimer’s disease and other neurodegenerative dis-
eases because they can be used for cellular investigation
of mechanisms and drug screening in vitro. While, to
date, most human iPSC models have been derived from
rare monogenetic familial forms of neurodegenerative
disease, most patients have sporadic disease forms for
which post-mortem neuropathological examination is
essential for definitive diagnosis. In some cases, tissue
from patients with similar symptoms may exhibit quite
different pathology. For instance, vascular dementia or
frontotemporal lobar degeneration, which can clinically
present as AD, may not be correctly diagnosed until post
mortem examination of the brain. If tissue from de-
ceased patients that had undergone neuropathological
evaluation could be used to generate iPSCs, knowledge
of the definitive diagnosis as well as potential stratifica-
tion of sporadic patients could guide the selection and* Correspondence: jc2892@cumc.columbia.edu; SNoggle@nyscf.org
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stated.subsequent use of the cell lines to be made. While gen-
eration of iPSCs from fresh autopsy tissue has recently
been reported [1,2], brain bank networks, which contain
tens of thousands of samples, could provide a much larger,
and more immediate, source of tissue. As these biobanked
tissues have not been specifically processed for the deriv-
ation of living cells, we have investigated whether it is pos-
sible to use them to isolate somatic cells and subsequently
reprogram these into iPSCs. This would allow access to
large numbers of neuropathologically defined cases, in-
cluding patients with rare diseases whose frequency is
low in clinical populations.Methods
Cell culture
All media components were obtained from Life Technolo-
gies unless otherwise indicated. Dural/scalp outgrowths,
established fibroblast lines, and mouse embryonic fibro-
blasts (MEFs, GlobalStem) were grown in fibroblast
media, defined as the following: DMEM/10% FBS/
Glutamax (2 mM)/2-Mercaptoethanol (0.1 mM)/Peni-
cillin-streptomycin (100 U/mL-0.1 mg/mL). For initial
plating of new dural and scalp samples, the tissue was first
grown in biopsy media: DMEM/10% FBS/Glutamax
(2 mM)/2-Mercaptoethanol (0.1 mM)/MEM non-essentialLtd. This is an Open Access article distributed under the terms of the Creative
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sides (1×, Millipore). Reprogrammed iPSCs were maintained
on MEFs, in HUESM: KO-DMEM/20% KSR/Glutamax
(2 mM)/2-Mercaptoethanol (0.1 mM)/bFGF (10 ng/ml)/
Penicillin-streptomycin (100 U/mL-0.1 mg/mL). iPSCs
were enzymatically passaged using TrypLE and replated in
the presence of a Rho-kinase inhibitor (Y27632, Stemgent).
Karyotyping and DNA fingerprinting of fibroblasts and
iPSCs was performed by Cell Line Genetics (Madison,
Wisconsin). Directed and undirected differentiations are
described below.
Generation of postmortem tissue outgrowths
De-identified donated postmortem brain tissue was ob-
tained through the New York Brain Bank at Columbia
University. Neuropathological examination was per stan-
dardized protocols [3,4]. For the pilot study, scalp and
dural tissue from the same patient was frozen at the time of
autopsy in the presence of 10% DMSO/45% FBS/45% fibro-
blast media. Subsequent experiments utilized standard
banked material that was frozen via a liquid nitrogen vapor
sandwich method [3,4]. Dural tissue was stored as rolled
tissue (approximately 1 cm by 5 cm in 2 ml cryovials that
have been stored at −80 degrees for 1–11 years. Samples
were either thawed entirely for 1 min at 37°C for processing
or quickly removed from the vial with forceps while still
frozen and a small piece was cut off using a scalpel, to pre-
serve unthawed tissue for future use. Samples were washed
twice with PBS and DMEM, then cut into smaller pieces,
approximately 2–3 mm by 2–3 mm. One drop of sterile sil-
icon grease was placed in the center of each well of a 6-well
cell culture plate and four or five pieces of the tissue were
placed around each drop. A coverslip was placed on top of
the silicon/samples and 2 ml of biopsy culture media were
added to each well. Samples were left undisturbed for five
days and then checked for fibroblast outgrowth. Media was
switched to fibroblast culture medium and changed every
other day. Outgrowth was monitored and fibroblasts were
passaged with TrypLE to a new 6-well culture dish when
the coverslip and/or plate became at least 50% confluent.
Fibroblast cultures were expanded and passaged until suf-
ficient numbers were generated for reprogramming and
cryogenic preservation.
Reprogramming using Sendai virus
Fibroblasts between passages 3 and 5 were plated into a
12-well cell culture plate format at 50,000 cells per
well in fibroblast culture medium. CytoTune-iPS kits
(Life Technologies) containing four Sendai virus vec-
tors (Oct3/4, Sox2, Klf4, c-Myc) were used to infect fi-
broblasts at an MOI = 3 (transduction volume based
on the specific titer of each lot), in fibroblast media. The
day after infection, an additional 1 mL of fibroblast media
was added to the culture. The next day, the media wasswitched to HUESM and depending on the severity of
Sendai toxicity, MEFs were overlaid on some of the
cultures. The medium was changed every day until
colonies appeared. Colonies were manually picked and
expanded on MEFs.
Dural and scalp fibroblast gene expression profile
RNA was prepared using the RNeasy mini kit (Qiagen) per
the manufacturers instructions. cRNA was amplified using
the Illumina TotalPrep RNA Amplification Kit (Ambion)
and run on an Illumina HT_12_v4 BeadChip Array
(Ilumina), as per the manufacturer’s instructions. Analysis
of microarray data was performed using Genome Studio
software (Illumina).
Immunostaining for pluripotency markers and alkaline
phosphatase assay
For pluripotency staining, cultures were fixed using 4%
paraformaldehyde (PFA, Santa Cruz) for 12 min at room
temperature. After multiple PBS washes the cells were
treated with PBS containing 0.1% Triton X-100 (Sigma)
and 10% normal donkey serum (Jackson Immuno Research)
for 1 hr. Cells were then treated with primary antibodies in-
cluding Tra-160 (1:200, Millipore), SSEA-4 (1:500, Abcam),
Tra-181 (1:200, Millipore), OCT-4 (1:500, Stemgent),
Nanog (1:100, Cell Signaling), and SOX-2 (1:500, Stemgent).
Alexa-conjugated anti-mouse or anti-rabbit IgG second-
ary antibodies were used (Invitrogen). AP staining was
performed with the Vector Red Alkaline Phosphatase
Substrate Kit (Vector Laboratories) per the manufacturers
instructions. Nuclei were counterstained with Hoechst
33342 (Sigma).
Nanostring nCounter assay
Total RNA was isolated from each iPSC line using the
RNeasy kit (Qiagen) as per the manufacturers instructions.
100 ng of RNA for each sample was analyzed with the
NanoString nCounter system (NanoString, Seattle, WA)
using a pre-designed codeset. The codeset contains 25
probes for detection of retroviral and Sendai viral trans-
genes, pluripotency, spontaneous differentiation markers,
and housekeeping genes [5]. Data was normalized to
the geometric mean using nSolver Analysis Software
v1.0 (NanoString) and compared with previous runs of
a Sendai-positive control line, a fibroblast line (1043),
and two human ESC lines (HUES42 and HUES16).
In vitro pluripotency assay
Undirected embryoid bodies (EB) were formed by placing
10,000 iPSCs in multiple wells of a 96-well non-tissue
culture treated V-bottom plate (Evergreen) containing
HUESM plus 10 μM ROCKi (Stemgent), and underwent
brief centrifugation. After 14 d of culturing EBs were trans-
ferred into a 6 well low attachment plates (Corning) and
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were fixed in 4% paraformaldehyde for 20 min at room
temperature and processed in 15% and 30% sucrose so-
lutions for one day each at 4°C. EBs were then embed-
ded in O.C.T. (Sakura Finetek) and cryosectioned. The
sections were blocked in PBS containing 0.1% Triton X-
100 and 10% donkey serum for 1 hr at room temperature,
followed by an overnight incubation at 4°C with antibodies
identifying the 3 germ layers: SMA (1:500, DAKO), AFP
(1:500, DAKO) TuJ1 (1:500, Covance), Sox17 (1:500,
R&D Systems). Alexa-conjugated anti-mouse or anti-
rabbit IgG secondary antibodies were used (Invitrogen)
along with Hoechst 33342 counterstain. Sections were
set with Vectashield Hard Set Mounting Media (Vector
Laboratories).
Teratoma assay
Two confluent wells of iPSC line ASC-7D-AD (p.25)
were chemically disassociated using dispase (Gibco) and
centrifuged for 4 minutes at 800 rpm. For each well,
cells were resuspended as clumps in 100 μL of HUESM
and added to 100 μl of Matrigel (BD Biosciences) on ice.
A three-month-old NSG immune-compromised mouse
(Jackson Laboratory) was anaesthetized with isofluorane
and injected subcutaneously with a cell-suspension on
each dorsal flank, and was sacrificed 75 d post injection.
The teratoma was manually extracted, fixed in 4% PFA
overnight and embedded in paraffin. Sections were
stained with hematoxylin and eosin and histologically
examined for developmental germ layers.
Directed neuronal differentiation
MEFs were manually removed and iPSCs were brought to
single cells suspension using Accutase (Life Technologies)
and plated into a 48-well plate coated with polyornithine
(100 μg/mL, Sigma Aldrich)/laminin (3 μg/mL, Invitrogen)
at 25,000 cells per well, in mTeSR1 (Stem Cell Technologies)
and 10 μM ROCKi. Cells were allowed to recover for
2 days before being switched to custom mTeSR1 (missing
five growth factors, Stem Cell Technologies) containing
10 μM SB421542 (Stemgent) and 250 nM LDN193189
(Stemgent). Media was changed completely every 2 days.
At Day 11, media was gradually switched with half feeds
for the first two changes to neuronal differentiation
medium (Neurobasal/B27 without retinoic acid/Glutamax
(2 mM)/Penicillin-streptomycin (100 U/mL-0.1 mg/mL).
At days 14 and 21, wells were washed with PBS and fixed
using 4% PFA for 12 min at room temperature. After three
PBS washes, cells were blocked with 0.1% Triton X-100
and 10% normal donkey serum for 1 hr. Cells were treated
with primary antibodies including PAX6 (1:300, Covance),
Tuj1 (1:500, Covance), and Sox1 (1:400, Stemgent).
Alexa-conjugated anti-mouse or anti-rabbit IgG secondary
antibodies were utilized (Invitrogen).Results
Generation of iPSCs from skin biopsies is routinely
preformed by our and many other laboratories [5], but
whether iPSCs with similar properties can be generated
from meninges was unclear. To answer this question, we
generated dural fibroblasts from the skin (scalp) and cranial
dura mater tissues from a random autopsy subject from the
CUMC brain bank series. This patient had multiple system
atrophy (MSA), a fatal disease characterized by glial cyto-
plasmic inclusions composed of α-synuclein that affects the
striatum and other brain regions [6] (Figure 1A-D). The tis-
sue was frozen at autopsy using 10% DMSO/45% FBS/45%
fibroblast media, a standard cryoprotection medium. Upon
subsequent culture, samples taken from both tissues ex-
hibited outgrowths with fibroblast morphology. Cell lines
derived from these outgrowths were termed ASC2S-MSA
and ASC2D-MSA (i.e. autopsy stem cell subject 2 skin
and dura, ASC2S-MSA and ASC2D-MSA, respectively,
Figure 1E,I). Gene expression profiling shows that the skin
and dural fibroblast lines have similar but distinct gene ex-
pression profiles (correlation coefficient 0.86), suggesting
that the endosteal-derived dural fibroblasts have unique
features. Comparing nine genes commonly used as func-
tional fibroblast markers [7] reveals that most are present
at similar levels in scalp and dural cells, with the exception
of FSP1 (Additional file 1). In summary, both scalp and
dural tissues yield outgrowths of fibroblast identity, albeit
likely of different subclasses.
Next, we attempted to reprogram skin and dural lines
into a pluripotent state using a Sendai virus integration-
free method [8]. After viral infection, both ASC2S-MSA
and ASC2D-MSA lines produced colonies with iPS-like
morphology. Individual clones were manually picked, ex-
panded, and characterized for stem cell properties such
as pluripotency (Figure 1F-H, J-R). ASC2S-MSA-CP and
ASC2D-MSA-CP iPSCs (cryoprotected) also displayed a
normal female karyotype and fingerprinting confirmed
that both lines were derived from the same subject
(Additional file 1 and data not shown). These results indi-
cate that both scalp and dural cells can be reprogrammed
to produce high-quality iPSCs.
Based on these results, we attempted to generate iPSCs
from nine additional dural samples obtained from control
individuals or from subjects with late-onset AD, all of
which had been frozen and archived without a cryoprotect-
ant such as DMSO, using a commonly utilized liquid nitro-
gen vapor sandwich method [3,4]. We obtained successful
fibroblast outgrowths from four of the nine samples,
although one of these outgrowths produced insufficient
cells to reprogram (ASC9D). A second line was lost to con-
tamination (ASC8D). When the remaining two lines were
infected with Sendai virus, one (ASC7D-AD) formed col-
onies with iPSC morphology. This sample, stored at −80°C
for 9 years, was from a patient with pathological changes
Figure 1 Cryoprotected MSA patient outgrowths. Scale bars are 1 cm for (A-B) and 100 μm for (C-L, O-R). (A) Gross examination of a right
coronal section through the fresh brain reveals discoloration and atrophy of the globus pallidus and putamen. (B) Examination of the midbrain
reveals pallor of the substantia nigra. (C) Luxol-fast blue/hematoxylin and eosin stained sections demonstrate glial cytoplasmic inclusions
(Papp-Lantos bodies) in the subcortical white matter. (D) These inclusions are highlighted by immunohistochemical staining to α-synuclein.
(E,I) Outgrowths with fibroblast morphology from the scalp (ASC2S-MSA; E) and dura mater (ASC2D-MSA; I). (F-H, J-L) Immunostaining of scalp
(ASC2S-MSA-CP) and dura (ASC2D-MSA-CP) iPSCs demonstrates expression of pluripotency markers as indicated. AP stands for alkaline-phosphatase.
DNA is in blue. (M-N) Nanostring analysis for endogenous stem cell genes (M) and shutoff of Sendai transgenes (N). Hues16 and Hues42 were used as
positive controls for endogenous stem cell genes, unrelated fibroblasts as a negative control, and infected unrelated fibroblasts as a positive control for
Sendai transgene expression. (O-R) Undirected EBs were cryosectioned and immunostained for the 3 developmental germ layers: endoderm (AFP),
mesoderm (SMA), and ectoderm (Tuj1).
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Figure 2 Generation of iPSCs from non-cryoprotected dura. Scale bars are 1 cm for (A) and 100 μm for (B-M). (A) Gross examination of a
coronal right hemi-section from the brain of a sporadic AD patient (case ASC7) illustrates atrophy and ventricular dilatation. Immunohistochemical
staining for amyloid-β (Aβ) peptide and hyper-phosphorylated tau confirms pathological accumulation of amyloid plaques and neurofibrillary
tangles (insets). Scale bar is 1 cm. (B) Fibroblast-like outgrowths from the thawed archived dura from the same subject, 18 days post plating.
(C-N) Characterization of a representative iPSC clone (clone 4) derived ASC7D-AD. (C-E) Immunofluorescence staining using antisera targeting
(C) Nanog (green), Tra160 (red); (D) Sox2 (green), SSEA4 (red); (E) Oct4 (green) alkaline phosphatase (red) confirms pluripotency. Nuclei are
counterstained with Hoechst 33342 (blue). (F-G) Undirected EBs were cryosectioned and immunostained for the three developmental germ
layers: endoderm (Sox17), mesoderm (SMA), and ectoderm (Tuj1). (H-J) Teratomas were sectioned and hematoxylin and eosin stained, and show
evidence of the presence of the three developmental germ layers as indicated. (K-L) Nanostring analysis for endogenous stem cell genes (K), and
shutoff of Sendai transgenes (L). (M) Immunofluorescence staining using antisera targeting neuron-specific class III β-tubulin (Tuj1, green) and the
neural progenitor marker paired box 6 (PAX6, red) demonstrates directed neuronal differentiation (21 days). Nuclei are counterstained with DAPI
(blue). (N) This iPSC line displays a normal female karyotype.
Table 1 Successful dural outgrowths and iPSC generation
Sample CP Sex Age Class. iPSCs PMI (Frozen)
ASC2S/D Y F 47 MSA 3+ clones 14’24”
ASC7D N F 79 AD 3+ clones 7’40”
ASC8D N F 54 Control Contaminated 15’40”
ASC9D N F 78 AD Insufficient # 34’55”
ASC12D N M 68 Control Failed 20’46”
ASC14D N F 78 AD N/A 34’55”
ASC15D N F 79 AD N/A 7’40”
ASC19D N M 60 ALS 2+ clones 11’45”
ASC21D N M 89 Control Failed 7’17”
ASC22D N F 54 Control Failed 15’40”
ASC24D N M 72 DLBD Failed 23’55”
ASC27D N M 63 HD 2+ clones 14’55”
ASC30D N F 76 PD 2+ clones 13’34”
Abbreviations. For sample, S refers to skin as tissue of origin, D refers to dura
mater. CP stands for cyroprotection. Class stands for classification, which
includes MSA (multiple systems atrophy), AD (Alzheimer’s disease), ALS
(amyotrophic lateral sclerosis), DLBD (diffuse Lewy body disease), HD
(Huntington’s disease), and PD (Parkinson’s disease). For iPSC generation, N/A
(not applicable) indicates no reprogramming was attempted although the
number of outgrowth cells was sufficient. PMI refers to post mortem interval,
and refers to the amount of time after death before the sample was frozen in
hours (’) and minutes (”).
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frequent amyloid plaques (CERAD plaque score C [9]) and
severe accumulation and progression of phospho-tau inclu-
sions (Braak neurofibrillary tangle stage VI, Figure 2A [10]).
Three individual clones were manually picked and ex-
panded with the clone displaying the best morphology se-
lected for further characterization, including confirmation
of endogenous expression of stem cell genes by immuno-
staining and Nanostring analysis [5], verification of Sendai
transgene shutoff, establishing pluripotency both in vitro
(embryoid body assay) and in vivo (teratoma), and directed
differentiation into neurons (Figure 2B-M). ASC7D-AD had
a normal female karyotype and matched the parent dural fi-
broblasts by fingerprinting (Figure 2N and data not shown).
To replicate our finding that non-cryoprotected archival
dura mater can be used to generate iPSCs, we acquired 18
additional biobanked cranial dura samples from a cohort
of subjects with an assortment of neuropathologies. We
obtained fibroblast outgrowths from eight of these tissues
(Table 1). As with our first attempt, it took longer to pro-
duce outgrowths than fresh skin biopsies: 11–30 days with
an average of 17 days for frozen dural samples as com-
pared to 5–10 days for fresh skin biopsies.
Sendai virus-mediated reprogramming was success-
ful in three of six lines, including samples from
neuropathologically-confirmed sporadic amyotrophic
lateral sclerosis (ALS), Huntington’s disease, and
Parkinson’s disease (Table 1). These tissues had been
stored at −80°C for 10–11 years. Post mortem interval
before freezing ranged between 4.5 hours and 39 hours,
and did not correlate with either successful outgrowth or
subsequent reprogramming. Two clones from each line
were manually picked and expanded, and the clone with
best morphology was further characterized. Similar to
what was done for ASC2D/S-MSA and ASC7D-AD re-
programming, additional clones (at least 2+ per line) were
frozen in bulk for potential future use. While the repro-
gramming efficiency was not as high as fast growing fresh
skin biopsies (easily 20+ colonies under good conditions),
it was sufficient to allow one to study a handful ofclones if desired. In each case, Nanostring assays and
immunostaining for endogenous stem cell markers
confirmed successful reprogramming and Sendai trans-
gene shutoff, embryoid bodies confirmed pluripotency,
and iPSCs had the capacity to undergo directed differenti-
ation into neural cells (Figure 3 and Additional file 2).
ASC19D-ALS (amyotrophic lateral sclerosis) and ASC30D-
PD (Parkinson’s disease) cell lines had normal karyo-
types, although multiple clones of ASC27D-HD (male
Huntington’s disease subject) lacked the presence of a
Y chromosome (data not shown). PCR amplification of
the AMG gene, which can produce different amplicon
sizes depending if AMG is located on the X or Y chromo-
some, suggests that the Y chromosome was lost in the
Figure 3 Characterization of additional dura-derived iPSCs. All scale bars are 100 μm and representative clones are shown. ASC19D-ALS
(clone 1) is from a sporadic ALS case. ASC27D-HD (clone 2) is from a Huntington’s disease case. ASC30D-PD (clone 1) is from a sporadic
Parkinson’s disease case. (A-C) Outgrowth with fibroblast morphology from dura mater. (D-L) Immunostaining for pluripotency markers as
indicated. AP stands for alkaline-phosphatase. DNA is in blue. (M-R) Undirected EBs were cryosectioned and immunostained for the three
developmental germ layers: endoderm (AFP), mesoderm (SMA), and ectoderm (Tuj1). (S-U) iPSC-derived neurons (Tuj1) and neural progenitors
(Pax6) after 14 days of directed neuronal differentiation. DNA is in blue.
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DNA from the original dural tissue (data not shown). In
summary, fourteen of twenty-five (56%) dural samples
produced fibroblast outgrowths, and four of nine (44%)
outgrowths were successfully reprogrammed.Discussion
These results demonstrate the potential to leverage existing
biorepositories to support research in a powerful new way.
While tissue banks in various forms have existed for
over 60 years, demand for human tissue for personalized
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large biorepositories, has accelerated the rate of establish-
ment of new facilities [11,12]. A recent survey has identified
at least 636 U.S. biobanks, 36% of which have postmortem
tissue, 9% exclusively (largely brain banks) [11]. Archival
specimens that were not intended for iPSC generation at
the time of harvesting have the potential to be unlocked for
functional studies to test mechanistic hypotheses. Pre-
liminary results suggest other banked brain tissues, in-
cluding leptomeninges and the large artery associated
with the choroid plexus, can also produce outgrowths
both morphologically similar and distinct from fibroblasts
(data not shown). In addition, while many collections store
solid tissues, there are other specimens within these banks
that might be suitable for generating stem cell lines in the
future, including blood, saliva or buccal cells, cord blood
and pathological body fluids (e.g, ascites), among others
[11]. The majority of biobanks focus on a single disease
group, with neoplasia, neurodegeneration and HIV/AIDS
being the most common, but there is a rich diversity of dis-
eases represented in these collections that include both
common and rare diseases, many of which currently have
no cellular models. In the case of Alzheimer’s disease, the
Alzheimer’s Disease Education and Referral Center (ADEAR)
currently lists 27 NIA funded Alzheimer’s disease centers,
each containing a neuropathology core that routinely
banks frozen tissue (http://www.nia.nih.gov/research/
dn/alzheimers-disease-centers-adcs). While the total
number of specimens available for generating iPSCs is
difficult to estimate, the National Alzheimer’s Coordinating
Center (NACC) has autopsy data from ~13,279 subjects
from these centers as of June 1st, 2013 (https://www.alz.
washington.edu/WEB/data-descript.html), the majority
of which have frozen tissue available.Conclusions
There is a vital need for well-characterized patient ma-
terial for translational research [13]. Deriving iPSCs from
tissue from patients with neurodegenerative diseases
with post-mortem confirmation, which remains the gold
standard, is highly advantageous over utilization of lines
from patients with clinical ascertainment alone in that
there is certainty in the diagnosis. This approach has the
additional benefit of having post-mortem brain tissue
available for rapid correlation and cross validation of
neuropathological and cellular findings.Additional files
Additional file 1: Related to Figure 1. Characterization of scalp and
dura-derived iPSCs. This figure shows the relative expression of fibroblast
genes for scalp and dural outgrowths from the same MSA patient, as
shown in Figure 1, as well as karyotype data for these lines.Additional file 2: Related to Figure 3. Additional characterization of
dura-derived iPSCs. This figure shows additional Nanostring analysis for
endogenous stem cell genes and shutoff off Sendai transgenes for
additional iPSC lines.
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